Cervical Cancer Screening: HPV Primary Testing and Updated Intervals
Current Screening Recommendations
The 2020 ACS guideline and the 2023 USPSTF update both endorse three acceptable screening strategies for average-risk women: HPV primary testing alone every 5 years (preferred by ACS), co-testing (HPV plus cytology) every 5 years, or cytology alone every 3 years. The ACS recommends initiating screening at age 25, while the USPSTF maintains age 21 as the starting point. For women aged 21-24, cytology alone every 3 years remains appropriate if the USPSTF framework is followed. Screening can be discontinued after age 65 with adequate prior negative screening (3 consecutive negative cytology results or 2 consecutive negative HPV or co-test results within the prior 10 years, with the most recent within 5 years).
HPV Primary Testing: Evidence Base
The ATHENA trial (n=47,208) demonstrated that HPV primary testing with genotyping for HPV 16/18 detected 61% more CIN3+ lesions than cytology alone over 3 years. The HPV FOCAL trial (n=19,009) confirmed that a single round of HPV testing provided greater protection against CIN3+ than cytology with follow-up colposcopy referral. The FDA-approved Roche cobas HPV test and BD Onclarity HPV assay provide concurrent genotyping, allowing immediate colposcopy referral for HPV 16/18-positive results (CIN3+ risk of 8-10%) and 1-year repeat testing for other high-risk HPV genotypes (CIN3+ risk of 2-3%).
Managing Abnormal Results: The 2019 ASCCP Consensus
The 2019 ASCCP risk-based management guidelines replaced prior result-specific algorithms with a unified framework based on estimated CIN3+ risk, integrating current and prior test results. The clinical action thresholds are: immediate colposcopy for CIN3+ risk of 4.0% or higher, 1-year surveillance for risk 0.55-3.9%, 3-year surveillance for risk 0.15-0.54%, and 5-year return to screening for risk below 0.15%. This framework allows patient-specific management, for example: HPV16-positive with NILM cytology (CIN3+ risk 4.3%) proceeds to colposcopy, while HPV other type-positive with NILM cytology (CIN3+ risk 0.9%) undergoes 1-year repeat testing.
Sponsored
HPV Vaccination Impact on Screening
The 9-valent HPV vaccine (Gardasil 9) covers HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, which collectively account for approximately 90% of cervical cancers. Population-level data from Australia (13 years post-vaccination program) show a 77% reduction in high-grade cervical abnormalities in vaccinated cohorts. Sweden reported a 63% reduction in cervical cancer incidence in women vaccinated before age 17 (Lei et al., 2020, NEJM). While current screening guidelines apply regardless of vaccination status, modeling studies suggest that in fully vaccinated populations, screening initiation may safely be delayed to age 30 with extended 7-10 year intervals.
Self-Collection and Access Innovations
Self-collected vaginal HPV testing has emerged as a strategy to increase screening access. The PREVENTT trial (n=8,986) demonstrated that self-collected HPV testing had sensitivity of 86% for CIN2+ compared to 96% for clinician-collected samples, with specificity of 87% versus 84%. The HOME trial showed a 96% increase in screening uptake among never/under-screened women offered self-collection kits. The WHO now recommends self-collection as an option for HPV-based screening. In the US, the FDA-approved Teal Health self-collection device became available in 2024, potentially reaching the 14 million women who are overdue for cervical cancer screening.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.